Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats

Human Reproduction

Volumn 28, Issue 11, 2013, Pages 3074-3085

  Zhang, Xinlin ^a   Zhang, Chengwei ^a   Shen, Shanmei ^a   Xia, Yan Jie ^a   Yi, Long ^a   Gao, Qian ^a   Wang, Yong ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

dehydroepiandrosterone; fibrosis; metformin; polycystic ovary syndrome; simvastatin

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; MESSENGER RNA; METFORMIN; PRASTERONE; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OUTCOME ASSESSMENT; OVARIAN HYPERFIBROSIS; OVARY DISEASE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE HYPERFIBROSIS; UTERUS DISEASE; WESTERN BLOTTING;

RATTUS;

DEHYDROEPIANDROSTERONE; FIBROSIS; METFORMIN; POLYCYSTIC OVARY SYNDROME; SIMVASTATIN;

ANIMALS; DEHYDROEPIANDROSTERONE; FEMALE; FIBROSIS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; METFORMIN; OVARIAN DISEASES; POLYCYSTIC OVARY SYNDROME; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; UTERINE DISEASES;

EID: 84885913361     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det341     Document Type: Article

References (53)

1. Abe Y, Murano M, Murano N, Morita E, Inoue T, Kawakami K, Ishida K, Kuramoto T, Kakimoto K, Okada T et al. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig Dis Sci 2012;57:335-344.
2. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: Prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92:456-461.
3. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: Prospective randomized trial. J Clin Endocrinol Metab 2009;94:4938-4945.
4. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89:2160-2165.
5. Burla AK, Lobato NS, Fortes ZB, OigmanW, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol 2013;165:483-487.
6. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, Georgiadou E, Hoffmann RG, Kissebah AH, Raptis S. Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44:525-531.
7. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: Results of a prospective, randomized trial. Fertil Steril 2006; 85:996-1001.
8. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: downregulation by cAMP. FASEB J 1999;13:1774-1786.
9. Hatzirodos N, Bayne RA, Irving-Rodgers HF, Hummitzsch K, Sabatier L, Lee S, Bonner W, Gibson MA, Rainey WE, Carr BR et al. Linkage of regulators of TGF-beta activity in the fetal ovary to polycystic ovary syndrome. FASEB J 2011;25:2256-2265.
10. Hu J, Yang J, Xu W, Li M. Study on the changes and clinical significance of serum transforming growth factor-beta, tumour necrosis factor-alpha and interleukin-6 in the patients with polycystic ovary syndrome. Chin J Birth Health Hered 2004;12:107-109.
11. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called ?hyperthecosis. Obstet Gynecol Surv 1982;37: 59-77.
12. Jordan CD, Bohling SD, Charbonneau NL, Sakai LY. Fibrillins in adult human ovary and polycystic ovary syndrome: Is fibrillin-3 affected in PCOs' J Histochem Cytochem 2010;58:903-915.
13. Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: A prospective, randomized, double-blind, placebo-controlled study. Fertil Steril 2010;94:2208-2213.
14. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453-2455.
15. Kenney MC, Zorapapel N, Atilano S, Chwa M, Ljubimov A, Brown D. Insulin-like growth factor-I (IGF-I) and transforming growth factor-b (TGF-b) modulate tenascin-C and fibrillin-1 in bullous keratopathy stromal cells in vitro. Exp Eye Res 2003;77:537-546.
16. Khattab S, Mohsen IA, Foutouh IA, Ramadan A, Moaz M, Al-Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:680-684.
17. King SM, Modi DA,Eddie SL, Burdette JE. Insulin and insulin-like growth factor signaling increases proliferation and hyperplasia of the ovarian surface epithelium and decreases follicular integrity through upregulation of the PI3-kinase pathway. J Ovarian Res 2013;6:12.
18. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
19. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007;196:402 e401-410.
20. Lembach KJ. Induction of human fibroblast proliferation by epidermal growth factor (EGF): Enhancement by an EGF-binding arginine esterase and by ascorbate. Proc Natl Acad Sci USA 1976;73:183-187.
21. Luchetti CG, Solano ME, Sander V, Arcos ML, Gonzalez C, Di Girolamo G, Chiocchio S, Cremaschi G, Motta AB. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol 2004; 64:59-74.
22. Manneras L, Cajander S, Holmang A, Seleskovic Z, Lystig T, Lonn M, Stener-Victorin E. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007;148:3781-3791.
23. Marcondes FK, Bianchi FJ, Tanno AP. Determination of the estrous cycle phases of rats: Some helpful considerations. Braz J Biol 2002;62:609-614.
24. Massam-Wu T, Chiu M, Choudhury R, Chaudhry SS, Baldwin AK, McGovern A, Baldock C, Shuttleworth CA, Kielty CM. Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta. J Cell Sci 2010;123:3006-3018.
25. McLennan SV,Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor ofmatrix metalloproteinase type 1:implications for diabetic nephropathy. Endocrinology 2004;145:5646-5655.
26. Miao Z,Wang Z, Yang Y, Chen L, Cui R,Wang X, Ou R. Role of TGF-b1 in the formation of ovarian interstitial fibrosis in PCOS rat. Reprod Contracept 2008;28:174-179.
27. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 1999; 181:153-159.
28. Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippelainen M, Perheentupa A, Tinkanen H, Bloigu R, Puukka K, Ruokonen A et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): A multicenter, double-blind, placebocontrolled randomized trial. J Clin EndocrinolMetab 2012;97:1492-1500.
29. Nakajima H, Nakajima HO, Salcher O, Dittie AS, Dembowsky K, Jing S, Field LJ. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res 2000; 86:571-579.
30. Pache TD, Chadha S, Gooren LJ, Hop WC, Jaarsma KW, Dommerholt HB, Fauser BC. Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology 1991;19:445-452.
31. Palomba S, Orio F Jr, Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068-4074.
32. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocr Rev 2009;30:1-50.
33. Qiang GF, Zhang L, Xuan Q, Yang XY, Shi LL, Zhang HA, Chen BN, Du GH. Effect of metformin on the formation of hepatic fibrosis in type 2 diabetic rats. Yao Xue Xue Bao 2010;45:801-806.
34. Qiao J. Prevalence of polycystic ovary syndrome in china. In: Second International Symposium on PCOS, Haerbing, China, 2008, pp. 174-175.
35. Riser BL, Cortes P, Yee J, Sharba AK, Asano K, Rodriguez-Barbero A, Narins RG. Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: Role of TGF-beta. J Am Soc Nephrol 1998;9:827-836.
36. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH et al. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83:4167-4171.
37. Rodrigues Diez R, Rodrigues-Diez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodriguez-Vita J, Mezzano S, Ortiz A, Egido J, Ruiz-Ortega M. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-beta-independent process. PLoS One 2010;5:e14145.
38. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related topolycysticovary syndrome(PCOS).HumReprod 2004;19:41-47.
39. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, Sanchez-Lopez E, Rodriguez-Vita J, Esteban V, Carvajal G, Plaza JJ, Egido J, Ruiz-Ortega M. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: Role of RhoA/ROCK and MAPK pathways. Hypertension 2007; 50:377-383.
40. Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 1986;103:2499-2509.
41. Schaafsma D, McNeill KD, Mutawe MM, Ghavami S, Unruh H, Jacques E, Laviolette M, Chakir J, Halayko AJ. Simvastatin inhibits TGFbeta1- induced fibronectin in human airway fibroblasts. Respir Res 2011;12:113.
42. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004;35:83-92.
43. Silfen ME, Denburg MR, Manibo AM, Lobo RA, Jaffe R, Ferin M, Levine LS, Oberfield SE. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682-4688.
44. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100:768-776.
45. Stewart DR, Dombroski BA, Urbanek M, AnkenerW, Ewens KG,Wood JR, Legro RS, Strauss JF 3rd, Dunaif A, Spielman RS. Fine mapping of genetic susceptibility to polycystic ovary syndrome on chromosome 19p13.2 and tests for regulatory activity. J Clin Endocrinol Metab 2006; 91:4112-4117.
46. Vandermolen DT, Ratts VS, Evans WS, StovallDW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-315.
47. Verheule S, Sato T, Everett Tt, Engle SK, Otten D, Rubart-von der Lohe M, Nakajima HO, Nakajima H, Field LJ, Olgin JE. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465.
48. Verrecchia F, Mauviel A. Transforming growth factor-beta and fibrosis.World J Gastroenterol 2007;13:3056-3062.
49. Xiao H,MaX, FengW, FuY, Lu Z, XuM, Shen Q, Zhu Y, Zhang Y. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 2010;87:504-513.
50. Xiong YL, LiangXY,Yang X, LiY,Wei LN. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol 2011;159:148-150.
51. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res 2008; 102:68-76.
52. Zhao J, Shi W, Wang YL, Chen H, Bringas P Jr, Datto MB, Frederick JP, Wang XF, Warburton D. Smad3 deficiency attenuates bleomycininduced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585-L593.
53. Zhu JQ, Zhu L, Liang XW, Xing FQ, Schatten H, Sun QY. Demethylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Mol Hum Reprod 2010;16:260-266.